BrainsWay Ltd. (Nasdaq: BWAY), a leader in health technology, has made a strategic investment of $2.3 million to acquire a minority stake in Axis Integrated Mental Health. This investment is part of BrainsWay’s ongoing efforts to expand access to deep transcranial magnetic stimulation (TMS) therapy for mental health treatment in the U.S.
Axis Integrated Mental Health, based in northern Colorado, offers a range of mental health services including TMS, Spravato, ketamine therapy, and care coordination. BrainsWay’s investment in Axis marks the company’s second major deal of the year, following a $5 million investment in Stella Mental Health earlier in 2025. The decision to invest in Axis comes after BrainsWay reported a 26% year-over-year revenue increase in the second quarter of the year.
This investment in Axis is part of BrainsWay’s larger strategy to acquire minority positions in leading U.S. mental health providers. By partnering with these providers, BrainsWay aims to expand access to TMS therapy and enhance mental health care services. The company’s ability to make these investments was made possible by a previous $20 million equity investment from Valor Equity Partners.
Hadar Levy, CEO of BrainsWay, highlighted the company’s commitment to investing in mental health providers and complementary enterprises during the recent earnings call. He emphasized that BrainsWay’s strategy allows the company to leverage its expertise in TMS technology while expanding market awareness and access to care.
The terms of the investment in Axis include an additional $1 million slated for investment after specific milestones are achieved. This minority stake is a preferred, annually compounding agreement that will increase in value over time. While the details of the milestones were not disclosed, the investment underscores BrainsWay’s confidence in Axis and its potential for growth.
TMS therapy has gained FDA approval for the treatment of depression, obsessive-compulsive disorder (OCD), and depression with anxiety symptoms. The market for TMS therapy is expected to reach $3 billion by 2033, reflecting the growing demand for alternative mental health treatments.
In addition to its investment in Axis, BrainsWay remains actively engaged with other mental health clinic enterprises for similar partnerships. The company’s investment activity signals a renewed focus on shaping the future of mental health treatment and expanding access to innovative therapies.
Overall, BrainsWay’s investment in Axis Integrated Mental Health demonstrates the company’s commitment to advancing mental health care and expanding access to cutting-edge therapies like deep TMS. As the field of mental health continues to evolve, partnerships like this one will play a crucial role in improving outcomes for patients and enhancing the overall quality of care.
